KARSTEN CREMER

Pharma Concepts was founded in 1999 by Dr Karsten Cremer, a European Patent Attorney and pharmaceutical scientist with industrial background. Dr Cremer has 20 years of academic and industrial experience in dosage form design, new technology development and commercialisation, technology assessment, and pharmaceutical IP issues.

In previous appointments, he was Director of Oral Drug Delivery at the largest German drug delivery company, LTS Lohmann Therapy Systems (Andernach, Germany), Chief Executive Officer of Capsulution NanoScience AG (Berlin, Germany), a nanotechnology company co-founded by the Max-Planck-Society, and Lecturer of Pharmaceutics at the University of Marburg.

His distinctive competencies include

• Establishing technology platforms for novel drug carrier systems
• Applying drug delivery technologies to create pharmaceutical products with superior performance
• Implementing intellectual property strategies to protect drug delivery research outcome
• Establishing freedom to operate for drug products
• Transferring technologies from academia to industry, and from science to practice
• Developing life cycle management strategies for pharmaceutical products using drug delivery technologies

In terms of technology, Karsten Cremer is particularly experienced in the fields of oral controlled release, orally disintegrating dosage forms, injectable sustained release systems, colloidal drug carrier systems, transmucosal delivery, gastroretentive devices, oral films and wafers.

Karsten Cremer is also known for his activities in the International Association for Pharmaceutical Technology (APV)  , where he is Head of the Drug Delivery Focus Group  , and in the Controlled Release Society (CRS)  , where he served several years as a member of the Board of Scientific Advisors and as President of the German Chapter.

In the leading Journal for the German pharmaceutical industry (pharmind – die pharmazeutische Industrie  ), Dr. Cremer publishes a monthly report on pharmaceutical innovations and patenting activities. Furthermore, he is author of about 190 patents and 20 book chapters, scientific publications and abstracts. He received several awards including the Redel Prize 1993 for an outstanding PhD thesis in the field of pharmaceutical technology, and the Carlo Erba Prize 1992 in oncology.